aleplasinin
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00684710)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasminogen activator inhibitor-1INHIBITOR
SERPINE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(-c2ccc3c(c2)c(C(=O)C(=O)O)cn3Cc2ccc(C(C)(C)C)cc2)c1- Mol. weight
- 425.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL325424 ↗
Also known as
- aleplasinin
- aleplasinin
- aleplasinin
- paz-417
- paz-417
- paz-417
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00739037 | Phase 1 | Aug 1, 2008 | Pfizer, Wyeth |
| NCT00663065 | Phase 1 | Apr 1, 2008 | Pfizer, Wyeth |
| NCT00684710 | Phase 1 | Apr 1, 2008 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1